



PROFICIENCY TESTING REPORT
ISHTM-AIIMS EXTERNAL QUALITY ASSURANCE PROGRAMME
 NABL accredited program as per ISO/IEC 17043:2010 standard
 Organized By Department of Hematology, AIIMS, New Delhi-110029



Duration of stability testing - minimum upto 8 days at ambient temp. after dispatch of specimens

EQAP CODE No. : 4158

Distribution No.: 163-K

Month/Year: April/2024

Instrument ID: med SOURCE

Model Name.: Eurocount5L

Serial No.: 862406062IEJCP

Name & Contact No. of PT Co-ordinator: Dr. Manoranjan Mahapatra (Prof. & Head), Hematology, AIIMS, Delhi,
 Tel: 9013085730 , E-Mail : info@ishtmaiimseqap.com

Date of issue & status of the report: 19-06-2024[Final].

CBC and Retic Assessment

| Test Parameters | S.No. | Among Lab (Accuracy Testing) | | | | | | Within Lab (Precision Testing) | | | |
|---------------------------|-------|------------------------------|---------------|-----------------------------|---------------------------------------------------|--------------------------------|---------|---------------------------------|-----------------------------------------------------|--------------------------------|---------|
| | | Your Result 1 | Your Result 2 | Your Results Sum of 2 Value | Consensus result sum of 2 values (Assigned Value) | Uncertainty of Assigned Values | Z Score | Yours Results Diff. of 2 Values | Consensus Result Diff. of 2 values (Assigned Value) | Uncertainty of Assigned Values | Z Score |
| WBC x10 ³ /µl | 1 | 4.65 | 4.49 | 9.14 | 8.55 | 0.033 | 0.70 | 0.16 | 0.1 | 0.006 | 0.67 |
| RBC x10 ⁶ /µl | 1 | 4.59 | 4.55 | 9.14 | 9.1 | 0.010 | 0.16 | 0.04 | 0.04 | 0.003 | 0.00 |
| Hb g/dl | 1 | 13.3 | 13.3 | 26.6 | 25.5 | 0.030 | 1.35 | 0 | 0.1 | 0.007 | -1.35 |
| HCT% | 1 | 39.7 | 39.1 | 78.8 | 79.2 | 0.170 | -0.09 | 0.6 | 0.4 | 0.023 | 0.54 |
| MCV-fl | 1 | 86.4 | 85.9 | 172.3 | 174 | 0.314 | -0.21 | 0.5 | 0.3 | 0.022 | 0.54 |
| MCH-Pg | 1 | 29.1 | 28.9 | 58 | 56.2 | 0.067 | 1.11 | 0.2 | 0.2 | 0.016 | 0.00 |
| MCHC-g/dl | 1 | 33.9 | 33.5 | 67.4 | 64.35 | 0.161 | 0.73 | 0.4 | 0.3 | 0.019 | 0.34 |
| Plt. x10 ³ /µl | 1 | 83 | 71 | 154 | 179.5 | 1.782 | -0.52 | 12 | 5 | 0.297 | 1.57 |
| Retic % | 2 | 15 | 14 | 29 | 16 | 0.260 | 1.83 | 1 | 0.5 | 0.036 | 0.84 |

P.S . Assesment

| YOUR REPORT | | | CONSENSUS REPORT | |
|----------------|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|--|
| DLC% | 3 | Nrbcs=0 , Poly=0 L=88, E=4, Mono/Promono=0 , B1=0 P.M.=0, Mye=0, Meta=0, Other=Neutrophills:8 | Lymph: 77-88, Poly: 8-14.25, mono: 1-3, nRBC/Blast/Myelo/Meta/Eosino: 0-5 | |
| RBC Morphology | 3 | Normocytic normochromic | Predominantly: Normocytic/Normochromic; Moderate: Anisocytosis, Mild: Microcytic | |
| Diagnosis | 3 | CHRONIC LYMPHOPROLIFERATIVE DISEASE - SUGGESTIVE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | Chronic Lymphoproliferative Disorder/CLL | |

COMBINED DATA VALUES OF TOTAL PARTICIPANTS

| Test parameters | S.No. | Total participants covered in the current dist. 163--K | Total No. responded | % of Labs with Z Score 0-2 | | % of Labs with Z Score 2-3 | | % of Labs with Z Score >3 | |
|--------------------------------|-------|--------------------------------------------------------|---------------------|---------------------------------------------------------------------|------------|----------------------------|------------|---------------------------|------------|
| | | | | Among labs | Within lab | Among labs | Within lab | Among labs | Within lab |
| WBC x10³/µl | 1 | 303 | 303 | 79.21 | 89.44 | 5.61 | 5.28 | 15.18 | 5.28 |
| RBC x10⁶/µl | 1 | 303 | 303 | 89.44 | 90.76 | 5.28 | 3.96 | 5.28 | 5.28 |
| Hb g/dl | 1 | 303 | 303 | 90.1 | 91.42 | 5.61 | 3.96 | 4.29 | 4.62 |
| HCT% | 1 | 303 | 302 | 93.05 | 89.4 | 4.97 | 5.3 | 1.98 | 5.3 |
| MCV-fl | 1 | 303 | 302 | 92.05 | 85.1 | 5.3 | 7.28 | 2.65 | 7.62 |
| MCH-Pg | 1 | 303 | 302 | 87.09 | 92.38 | 6.95 | 4.64 | 5.96 | 2.98 |
| MCHC-g/dl | 1 | 303 | 302 | 93.05 | 93.38 | 3.64 | 3.31 | 3.31 | 3.31 |
| Plt. x10³/µl | 1 | 303 | 302 | 93.71 | 91.06 | 3.64 | 5.63 | 2.65 | 3.31 |
| ReticCount% | 2 | 303 | 251 | 95.22 | 86.85 | 3.19 | 7.17 | 1.59 | 5.98 |
| PS Assessment | 3 | 303 | 249 | Satisfactory :92.74%, Borderline Sat. :3.30%, Unsatisfactory :3.96% | | | | | |

***Comments:**

1). Among Lab (EQA) : Results acceptable.

2). Within Lab (IQA) : Precision acceptable.

Note-1: EQA (External Quality Assurance) : Your Performance among various of participating labs in PT, to determine the accuracy of your results.

IQA (Internal Quality Assurance) : Your Performance of comparison of two consecutive measurement values within your lab to test the precision of your autoanalyzer.

Note-2: Z score among & within lab were calculated, as per to ISO/IEC 13528:2015 standard. Z score among lab (EQA)= (Your Result Sum of two values - Consensus Result sum of two values)/(Normalised IQR)

Z score within lab (IQA)= (Your Result Difference of two values - Consensus Result difference of two values)/(Normalised IQR)

IQR = Quartile 3 - Quartile 1 of participant data, Normalised IQR = 0.7413 x IQR

Note-3: Z score 0 to ± 2 : Acceptable, Z score ± 2 to ± 3 :Warning Signal, Z score $> \pm 3$: Unacceptable [As per ISO/IEC 13528:2015 standard]

Note-4: Z score value between "0 to ± 2 " are texted in green colour. Z score value between " ± 2 to ± 3 " are texted in orange colour. Z score value $> \pm 3$ are texted in red colour.

Note-5: Homogeneity and stability testing of PT sample were done as per ISO 13528:2015 standard. To pass homogeneity test, between sample SD (Ss) should be smaller than the check value (0.3*SDPA). To pass the stability test, average difference in measurement values of first and last day sample ($\bar{x}-\bar{y}$) should be smaller than the check value (0.3*SDPA).

Note-6: ISHTM-AIIMS-EQAP does not subcontract any task of its scheme

Note-7: Participants are free to use methods/analyzer of their own choice.

Note-8: Proficiency testing (PT) samples are sent quarterly to each participant.

Note-9: All the necessary details regarding design and implementation of PT, are provided in the instruction sheet as well as on programme's website www.ishtmaiimseqap.com.

Note 10: Reports are kept confidential.

Report authorized by,



Dr. Manoranjan Mahapatra (Prof. & Head)

PT Co-ordinator: ISHTM-AIIMS-EQAP

Department of Hematology, AIIMS, New Delhi

-----End Of Report-----